CLGN vs ITGR vs NVCR vs ANIK vs HOLX

For growth investors, NovoCure Limited (NVCR) is the stronger pick with 8.

3% revenue growth year-over-year, versus -95. 3% for CollPlant Biotechnologies Ltd. (CLGN). Integer Holdings Corporation (ITGR) offers the better valuation at 30. 5x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Integer Holdings Corporation (ITGR) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Integer Holdings Corporation (ITGR) is the cheapest at 30.

5x versus Hologic, Inc. at 30. 5x. On forward P/E, Integer Holdings Corporation is actually cheaper at 14. 4x.

Over the past 5 years, Hologic, Inc.

(HOLX) delivered a total return of +16. 8%, compared to -97. 1% for CollPlant Biotechnologies Ltd. (CLGN). Over 10 years, the gap is even starker: ITGR returned +165. 7% versus CLGN's -95. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 45β versus NovoCure Limited's 2. 15β — meaning NVCR is approximately 373% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Anika Therapeutics, Inc. (ANIK) carries a lower debt/equity ratio of 17% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), NovoCure Limited (NVCR) is pulling ahead at 8.

3% versus -95. 3% for CollPlant Biotechnologies Ltd. (CLGN). On earnings-per-share growth, the picture is similar: Anika Therapeutics, Inc. grew EPS 80. 2% year-over-year, compared to -133. 9% for CollPlant Biotechnologies Ltd.. Over a 3-year CAGR, ITGR leads at 11. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hologic, Inc.

(HOLX) is the more profitable company, earning 13. 8% net margin versus -32. 3% for CollPlant Biotechnologies Ltd. — meaning it keeps 13. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HOLX leads at 17. 4% versus -33. 5% for CLGN. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Integer Holdings Corporation (ITGR) trades at 14.

4x forward P/E versus 17. 2x for Hologic, Inc. — 2. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 87. 3% to $33. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Hologic, Inc.

(HOLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 45), +124. 3% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 15 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HOLX: +124. 3%, NVCR: +38. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.